Novel Antimicrobial Dressing in Peripheral Intravenous Catheters (PIVCs)

Summary

The goal of this clinical trial is to compare a chlorhexidine impregnated dressing for peripheral intravenous catheters (PIVCs) to the standard dressing currently used in general medical and surgical inpatient wards.

The main questions it aims to answer are:

* Study Feasibility
* Occurrence of infectious complications related to the PIVC

Participants will be randomly allocated to receive either of the below dressings to cover and secure their PIVC:

* The standard dressing used at their hospital, or
* The intervention dressing which has Chlorhexidine gluconate (CHG) on it

Researchers will compare standard and CHG dressings to see if the presence of CHG improves the occurrence of infectious complications related to the PIVC.

Conditions

• Vascular Access Complication
• Device Related Infection
• Device Related Sepsis
• Device Site Reactions
• Catheter Infection
• Catheter Complications
• Catheter-Related Infections
• Catheter Related Complication
• Occlusive Dressings
• Wound Infection
• Wound of Skin
• Wound

Interventions

DEVICE

Chlorhexidine gluconate impregnated bordered polyurethane dressing

PIVCs will be dressed and secured at the participating sites * RBWH and PUH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with non-sterile tape over extension tubing. * QCH: PIVCs will be dressed with Tegaderm™ Antimicrobial I.V. Advanced Securement (9132) dressing and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.

DEVICE

Standard bordered polyurethane dressing

PIVCs will be dressed and secured as per standard practice at the participating sites * RBWH and PUH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1683) and non-sterile tape strip over extension tubing. * QCH: Bordered polyurethane dressing (Tegaderm™ IV Advanced 1682 or 1683) and secured with tubular bandage +/- arm board and non-sterile stretchy tape if PIVC over flexible joint, +/- tissue adhesive as per clinician preference.

Sponsors & Collaborators

• Queensland Children's Hospital

  collaborator OTHER_GOV

• Royal Brisbane and Women's Hospital

  collaborator OTHER_GOV

• Poitiers University Hospital

  collaborator OTHER

• Griffith University

  collaborator OTHER

• The University of Queensland

  lead OTHER

Principal Investigators

• Claire Rickard · The University of Queensland

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

6 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2023-05-03

Primary Completion

2024-06-03

Completion

2024-06-03

FDA Device

Yes

Countries

• Australia
• France

Study Locations